Phaseline

Targets › NT5E

NT5E (5'-nucleotidase): drug programs, companies and trials

10 programs from 8 companies in 26 trials: 13 Phase 1, 11 Phase 2, 2 Phase 3; Oncology; next expected readout Nov 2026.

Catalyzes the hydrolysis of nucleotide monophosphates, releasing inorganic phosphate and the corresponding nucleoside, with AMP being the preferred substrate. Shows a preference for ribonucleotide monophosphates over their equivalent deoxyribose forms. (UniProt, P21589)

Open in Phaseline: the race on NT5E, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecaOleclumab
5'-nucleotidase inhibitor
NT5EPhase 3Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer (NSCLC); Triple Negative Breast Neoplasms …Jan 2027
Arcus BiosciencesQuemliclustat
CD73 inhibitor
NT5EPhase 3Metastatic Pancreatic Ductal Adenocarcinoma; Gastrointestinal Tract Malignancies; Oligometastatic Prostate Cancer; Biliary Tract Carcinoma …Nov 2030
Bruno BockornyAGEN1423
Anti-CD73-TGFβ-Trap bifunctional antibody
NT5E, TGFB1Phase 2Advanced Pancreatic Ductal AdenocarcinomaApr 2027
AstraZenecaOleclumab
5'-nucleotidase inhibitor
NT5EPhase 1Carcinoma, Non-Small-Cell Lung; Metastatic Microsatellite-stable Colorectal CancerNov 2026
Jonsson Comprehensive Cancer CenterQuemliclustat
Adenosine pathway inhibitor; blocks adenosine production
NT5EPhase 1Borderline Resectable Pancreatic AdenocarcinomaDec 2026
AkesoAK119
anti-CD73 monoclonal antibody
NT5EPhase 1Colorectal Cancer; Solid Tumor, AdultDec 2026
Institut Paoli-CalmettesIPH5301
Anti-CD73 monoclonal antibody
NT5EPhase 1Metastatic CancerMar 2027
Servier Bio-InnovationS095024
Anti-CD73 antibody
NT5EPhase 1Non-small Cell Lung Cancer (NSCLC)Apr 2027
Phanes TherapeuticsMavrostobart (PT199)
anti-CD73 monoclonal antibody
NT5EPhase 1Non Small Cell Lung CancerDec 2027
AkesoAK131
anti-PD-1 and CD73 bispecific antibody
PDCD1, NT5EPhase 1Solid TumorDec 2028

Conditions

Pancreatic Ductal Adenocarcinoma (2) Non-Small Cell Lung Cancer (2) Borderline Resectable Pancreatic Adenocarcinoma (2) Metastatic Pancreatic Ductal Adenocarcinoma (1) Gastrointestinal Tract Malignancies (1) Oligometastatic Prostate Cancer (1) Biliary Tract Carcinoma (1) Locally Advanced Bladder Urothelial Carcinoma (1) Non-small Cell Lung Cancer (1) Metastatic Non-Small Cell Lung Cancer (NSCLC) (1) Triple Negative Breast Neoplasms (1) Metastatic Angiosarcoma (1)

Modalities

mixed (6), small molecule (3)

Companies

AstraZeneca (2) Akeso (2) Arcus Biosciences (1) Bruno Bockorny (1) Phanes Therapeutics (1) Jonsson Comprehensive Cancer Center (1) Servier Bio-Innovation (1) Institut Paoli-Calmettes (1)

Related targets

TGFB1 (1) PDCD1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.